ICON to Acquire Clinical Research Management

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, recently announced it has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management Inc. (ClinicalRM). The acquisition will enhance ICON’s ability to access the market for government-sponsored research and further enhances ICON’s capabilities in the areas of Vaccines and Infectious Disease.

ClinicalRM provides full-service and functional research solutions to a broad range of US government agencies. Their extensive expertise extends across basic and applied research, infectious diseases, vaccines development and testing, and the response to bio-threats. They have worked in collaboration with government and commercial customers to respond to the threat of global viral epidemics.

“The market for government-sponsored research is significant with over 1500 active clinical studies being funded by the National Institutes of Health or other federal agencies. ClinicalRM has strong relationships and a deep understanding of what is required to partner successfully with government sponsors .They will provide ICON a platform to further penetrate this market segment as part of our strategy to grow and diversify our customer base. ClinicalRM’s experience in responding to the challenges of global viruses will further enhance ICON’s capabilities in the areas of Vaccines and Infectious disease, benefiting our customers and patients globally,” said ICON’s Chief Executive Officer, Ciaran Murray.

“We are delighted to be joining ICON. By combining ClinicalRM’s expertise in government-sponsored research with ICON’s breadth of services and global footprint, we will be able to bring additional services and thought leadership to our customers. We are also excited about the potential the combination has to further innovate drug development in the area of Vaccines and Infectious diseases, important areas of focus for both government and commercial customers,” added Victoria Tifft, Chief Executive Officer of ClinicalRM.

ClinicalRM is a full-service Contract Research Organization specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs, and devices. The organization helps customers get their products to market faster with a wide array of research, regulatory, and sponsor services within the US and around the globe. From international partnerships and affiliations to government relations and local alliances, ClinicalRM delivers a synergy in the global market with projects spanning the government, academic, and commercial marketplaces. The company has a distinct ability to provide boots-on-the-ground and rapid response efforts to global health crises. For more information, visit www.clinicalrm.com.

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in the strategic development, management, and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,200 employees. For more information, visit www.iconplc.com.